Literature DB >> 17000035

Recombinant M. smegmatis vaccine targeted delivering IL-12/GLS into macrophages can induce specific cellular immunity against M. tuberculosis in BALB/c mice.

Zhengjun Yi1, Yurong Fu, Chun Yang, Junming Li, Xudong Luo, Quan Chen, Wei Zeng, Shan Jiang, Ying Jiang, Yonglin He, Jian Yang, Yehua Liu, Na Li, Dao-Yin Zhu.   

Abstract

In the present study, we constructed a viable therapeutic vaccine of recombinant M. smegmatis mediated IL-12/GLS (granulysin) gene transfer into murine macrophages to exert the immunotherapy effects on the Mycobacterium tuberculosis infection. We tested this recombinant therapeutic vaccine in an in vivo study to determine its capability of stimulating host specific immune responses against M. tuberculosis. BALB/c mice intranasally immunized with the therapeutic vaccine developed an efficient Th1 protective immune response against M. tuberculosis which was equal to that of the BCG strain. Inoculation intranasally with this viable vaccine induced high level of serum IFN-gamma, IL-12 and IgG2a. The viable vaccine was capable of inducing purified protein derivative (PPD) antigen-specific splenocytes proliferation and IFN-gamma production from T cells in spleens of the immunized mice. In addition, intranasally inoculation with the viable vaccine can induce PPD antigen-specific sIgA production in the broncho-alveolar lavage fluid (BALF) of the immunized mice. No change of IL-4 level was found in all groups. The therapeutic mechanism of this viable vaccine against M. tuberculosis infection observed here appeared to be a result of the specific Th1 immune response activated by mycobacterium antigen from M. smegmatis and the expression of sIL-12/GLS in alveolar macrophages via the M. smegmatis-mediated gene transfer method. This research demonstrates that the therapeutic gene can be introduced into a host by viable mycobacteria works to induce the host specific immune response against M. tuberculosis infection in vivo. Since this therapeutic vaccine can strongly induce specific Th1 responses against M. tuberculosis in BALB/c mice and has no obviously harmfulness to the host simultaneously, the recombinant vaccine might be a potential candidate therapeutic vaccine against tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17000035     DOI: 10.1016/j.vaccine.2006.08.037

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Inhalation of recombinant adenovirus expressing granulysin protects mice infected with Mycobacterium tuberculosis.

Authors:  J Ma; J Lu; H Huang; X Teng; M Tian; Q Yu; X Yuan; Y Jing; C Shi; J Li; X Fan
Journal:  Gene Ther       Date:  2015-07-16       Impact factor: 5.250

2.  Decreased serum granulysin levels in childhood tuberculosis which reverse after therapy.

Authors:  Diana Di Liberto; Simona Buccheri; Nadia Caccamo; Serena Meraviglia; Amelia Romano; Paola Di Carlo; Lucina Titone; Francesco Dieli; Alan M Krensky; Alfredo Salerno
Journal:  Tuberculosis (Edinb)       Date:  2007-03-26       Impact factor: 3.131

3.  A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis.

Authors:  Kari A Sweeney; Dee N Dao; Michael F Goldberg; Tsungda Hsu; Manjunatha M Venkataswamy; Marcela Henao-Tamayo; Diane Ordway; Rani S Sellers; Paras Jain; Bing Chen; Mei Chen; John Kim; Regy Lukose; John Chan; Ian M Orme; Steven A Porcelli; William R Jacobs
Journal:  Nat Med       Date:  2011-09-04       Impact factor: 53.440

4.  Anti-tuberculosis immunity induced in mice by vaccination with Mycobacterium smegmatis over-expressing Antigen 85B is due to the increased influx of IFNgamma-positive CD4 T cells into the lungs.

Authors:  Devin R Lindsey; Subramanian Dhandayuthapani; Chinnaswamy Jagannath
Journal:  Tuberculosis (Edinb)       Date:  2009-12       Impact factor: 3.131

5.  Genetic alteration of Mycobacterium smegmatis to improve mycobacterium-mediated transfer of plasmid DNA into mammalian cells and DNA immunization.

Authors:  Yongkai Mo; Natalie M Quanquin; William H Vecino; Uma Devi Ranganathan; Lydia Tesfa; William Bourn; Keith M Derbyshire; Norman L Letvin; William R Jacobs; Glenn J Fennelly
Journal:  Infect Immun       Date:  2007-07-30       Impact factor: 3.441

6.  Immunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in mice.

Authors:  Ping Wang; Limei Wang; Wei Zhang; Yinlan Bai; Jian Kang; Yanfei Hao; Tailai Luo; Changhong Shi; Zhikai Xu
Journal:  Hum Vaccin Immunother       Date:  2013-08-27       Impact factor: 3.452

7.  Protective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in mice.

Authors:  Shanmin Zhao; Yong Zhao; Fengfeng Mao; Caiqin Zhang; Bing Bai; Hai Zhang; Changhong Shi; Zhikai Xu
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

8.  The development of a novel Mycobacterium-Escherichia coli shuttle vector system using pMyong2, a linear plasmid from Mycobacterium yongonense DSM 45126T.

Authors:  Hyungki Lee; Byoung-Jun Kim; Bo-Ram Kim; Yoon-Hoh Kook; Bum-Joon Kim
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

9.  Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis.

Authors:  Ana Paula Junqueira-Kipnis; Fábio Muniz de Oliveira; Monalisa Martins Trentini; Sangeeta Tiwari; Bing Chen; Danilo Pires Resende; Bruna D S Silva; Mei Chen; Lydia Tesfa; William R Jacobs; André Kipnis
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

10.  Recombinant Bacille Calmette-Guérin coexpressing Ag85B-IFN-γ enhances the cell-mediated immunity in C57BL/6 mice.

Authors:  Wei Liu; Ying Xu; Hongbo Shen; Jingran Yan; Enzhuo Yang; Honghai Wang
Journal:  Exp Ther Med       Date:  2017-03-28       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.